Financial Performance - Operating loss of $44.7 million and net loss of $40.4 million, or $0.08 per share, for Q4 2025, compared to a net loss of $16.1 million, or $0.04 per share, for Q4 2024[18]. - Net loss for the year ended December 31, 2025, was $319.8 million, or $0.83 per share, compared to a net loss of $81.9 million, or $0.25 per share, for 2024[20]. - The company incurred a comprehensive loss of $319.844 million for the year ended December 31, 2025, compared to $81.943 million in 2024, indicating a worsening financial position[28]. - The loss per share increased to $0.83 in 2025 from $0.25 in 2024, reflecting the company's declining profitability[28]. Cash and Liquidity - Total cash of approximately $117.6 million as of December 31, 2025, with $11.4 million cash used in operations for Q4 2025[3]. - The company's cash balance rose to $117.633 million in 2025, compared to $3.480 million in 2024, indicating improved liquidity[26]. - The company expects to report around $154 million in liquidity by March 31, 2026, including undrawn credit facilities[4]. - Cash provided by financing activities increased significantly to $156,585 thousand in 2025, up from $40,686 thousand in 2024[32]. - The total cash at the end of 2025 was $117,633 thousand, a substantial increase from $3,480 thousand at the end of 2024[32]. Expenses - Exploration and evaluation expenses for Q4 2025 were $10.6 million, up from $8.3 million in Q4 2024, primarily due to increased share-based compensation[18]. - General and administrative expenses for Q4 2025 were $34.1 million, compared to $8.1 million for Q4 2024, reflecting increased share-based compensation and legal costs[19]. - General and administrative expenses surged to $99.772 million in 2025, compared to $30.644 million in 2024, highlighting a substantial rise in operational costs[28]. - Share-based compensation and expenses settled with equity amounted to $96,672 thousand in 2025, compared to $25,313 thousand in 2024[32]. Assets and Liabilities - As of December 31, 2025, the company reported total assets of $181.631 million, a significant increase from $62.998 million in 2024[26]. - The total liabilities increased to $215.074 million in 2025 from $80.116 million in 2024, indicating a significant rise in financial obligations[26]. - The company reported a royalty liability of $145 million in 2025, a substantial increase from $14 million in 2024, reflecting changes in its operational strategy[26]. Operational Developments - TMC USA holds an exclusive right of negotiation for a 50-year lease covering 1,466 acres at the Port of Brownsville, Texas, for developing a nodule processing and refining facility[10]. - TMC signed a Strategic Partnership Agreement with Mariana Minerals to conduct a feasibility study for a nodule processing facility in Brownsville, Texas[9]. - TMC USA submitted a consolidated application to NOAA for an exploration license and commercial recovery permit, increasing the expected recovery area to 65,000 km² with an estimated resource of 619 million tonnes of wet nodules[14]. - NOAA determined TMC USA's consolidated deep-seabed mining application is in substantial compliance, marking a key step in the U.S. regulatory process[13]. - The company plans to pursue commercial recovery of seafloor polymetallic nodules, with ongoing regulatory reviews and environmental assessments expected to impact future operations[24]. Shareholder Activity - The company raised $85,118 thousand from a private placement with Korea Zinc during the year[32]. - The company issued 19,623,376 common shares and warrants to Korea Zinc, raising $71,686 thousand[30]. - The company issued 12,333,333 shares under the 2025 Registered Direct Offering, netting $24,149 thousand[30]. - The total number of common shares outstanding increased to 422,966,333 by December 31, 2025, from 340,708,460 at the beginning of the year[30].

Financial Performance and Losses - The company incurred net losses of $25.1 million and $75.0 million in 2025 and 2024, respectively, with an accumulated deficit of $95.6 million as of December 31, 2025[122]. - The company has not generated any meaningful revenue since inception and expects to continue incurring significant losses as it develops its main platform technology, vCLAS[122]. - The company anticipates incurring significant costs associated with launching and commercializing its products, even if it generates revenues[137]. - The company’s operating results may fluctuate significantly, making future predictions difficult and potentially affecting share price[140]. - The company may face unforeseen expenses and complications in achieving its business objectives, which could impact its financial condition[126]. - The company has incurred net operating losses (NOLs) that may be limited due to ownership changes, affecting future tax liabilities[298]. Capital and Funding Needs - The company may need to raise additional capital to fund its development and commercialization plans, which could involve issuing equity or convertible debt securities[127]. - The company has outstanding indebtedness of $20,000,000 under Convertible Securities Notes, maturing on April 30, 2028, with an interest rate of 13% per annum[293]. - A new 1% U.S. federal excise tax on stock repurchases may apply to the company, impacting financial strategies[300]. Business Model and Market Risks - The company has a limited operating history and has not yet demonstrated the ability to successfully complete clinical trials or obtain regulatory approvals[125]. - The company’s future success depends on its ability to accelerate the commercialization of its products and capitalize on market opportunities[136]. - The company’s ability to execute its business model is dependent on various factors, including market acceptance of its products[144]. - The company's future growth and profitability depend on the acceptance of its products by hospitals, physicians, patients, and payors, which is uncertain[145]. - The total addressable market for the company's products may be smaller than estimated, which could impair sales growth[153]. Competition and Market Dynamics - The company faces intense competition for skilled personnel, impacting its research and development, clinical operations, and sales efforts[168]. - Consolidation in the medical device industry may lead to increased competition and potential revenue decreases due to price concessions[170]. - The life sciences industry is highly competitive, and the company must continuously improve its products to maintain revenue and market prospects[191]. Regulatory and Compliance Challenges - The company is subject to extensive regulations from the FDA and foreign agencies, which could result in significant expenses and delays if compliance is not met[286]. - The company may face significant legal liability, including fines and penalties, if it fails to comply with evolving data privacy and security regulations[262]. - The company must ensure compliance with HIPAA regulations to protect individually identifiable health information, which involves complex analyses and safeguards[264]. - The company faces challenges in transferring personal data due to stringent localization laws in the EEA and UK, which may impact its operations[266]. - Compliance efforts with healthcare laws and regulations will involve significant costs, and violations could lead to civil, criminal, and administrative penalties[273]. Intellectual Property and Legal Risks - The company relies on patent protection and other intellectual property rights, which may not adequately protect its competitive position and could lead to increased litigation costs[211]. - The company may face substantial costs and distractions from litigation related to intellectual property rights, which could adversely affect stock prices if perceived negatively by analysts or investors[226]. - The validity and enforceability of the company's patents could be challenged, impacting competition and financial performance[229]. - The company may not be aware of all third-party intellectual property rights, leading to potential disputes and significant costs[230]. Operational and Management Challenges - The company must upgrade internal business processes to manage anticipated growth effectively, which may strain operational capabilities[162]. - The company may seek acquisitions or strategic partnerships, which could divert management's attention and increase capital requirements[165]. - The success of the company largely depends on retaining key executives and scientists, with potential difficulties arising from losing key employees[167]. Product Development and Clinical Trials - Delays in clinical trials due to various factors could significantly increase product development costs and impact market entry[182]. - The first Ventricular Tachycardia ULTA procedure using the Adagio VT Cryoablation System was announced in September 2023, marking progress in clinical trials[183]. - The company has limited data on the safety and efficacy of its products, with earlier trial results not necessarily predicting future outcomes[185]. Market and Economic Conditions - Unfavorable global economic conditions, including pandemics and political instability, could adversely affect the company's ability to raise capital and its overall financial condition[171]. - Changes in tax laws could adversely affect the company's effective tax rate and cash flows, impacting overall financial performance[304]. Stock and Market Considerations - The market price of the company's common stock may fluctuate significantly due to various factors, including operating performance and market conditions, which could lead to volatility[316]. - The company may face challenges in maintaining an active trading market for its common stock, impacting liquidity and the ability to sell shares[319].

Financial Performance and Condition - The company recorded impairment charges of $232.2 million for the year ended December 31, 2025, with $228.4 million related to finite-lived intangible assets and $3.8 million related to property, plant, and equipment [123]. - As of December 31, 2025, the company's consolidated balance sheet included $33.3 million in inventories, $37.8 million in operating lease right-of-use assets, $30.3 million in property, plant, and equipment, and $2.8 million in intangible assets [122]. - The company has U.S. federal net operating loss (NOL) carryforwards of approximately $238.1 million as of December 31, 2025, which may be limited annually due to ownership change provisions [165]. - The company maintains a valuation allowance of approximately $149.1 million on the majority of its domestic and foreign net deferred tax assets as of December 31, 2025 [165]. - The company has a stockholder's deficit of approximately $(63) million as of December 31, 2025, failing to meet Nasdaq's Minimum Stockholders' Equity Requirement of $2.5 million [246]. - The market value of the company's listed securities was below $35 million, and it has realized a net loss in each of the past three fiscal years [246]. - The company anticipates material cash requirements for 2026, including principal and interest payments on its Term Loan, finance lease payments, and operating lease payments [344]. Operational Risks - The company experienced sales declines primarily due to agricultural oversupply, which may lead to lower margins, inventory write-downs, and additional impairments of long-lived assets [122]. - The company is exposed to manufacturing risks that could result in unexpected costs or liabilities, including equipment malfunctions and supply chain disruptions [128]. - The company is vulnerable to damage or loss of inventory due to accidents, natural disasters, or theft, which could harm its business operations [127]. - The company may face challenges in managing inventory effectively, leading to potential obsolescence and significant write-downs [125]. - Disruptions in freight carrier operations or increased shipping costs could negatively impact gross margins and financial results [136]. - A significant disruption in the supply chain or vendor relationships could materially impact the company's financial condition and results of operations [187]. Competitive Landscape - The company faces significant competition from established companies with greater financial and operational resources, which may affect its ability to generate revenues and capture market share [121]. - The company may not successfully develop new products or improve existing ones, which could adversely affect its market share and financial condition [117]. - Increased prices and inflation for raw materials and labor could negatively impact the company's margin performance and financial results [133]. Compliance and Regulatory Risks - The company faces risks associated with international operations, including compliance with local regulations and potential adverse tax consequences [137]. - The company is subject to numerous environmental laws that could impose additional costs and liabilities, affecting financial results [142]. - The company is required to maintain compliance with various regulatory standards, which may limit its flexibility in business operations and market strategies [182]. - Compliance with extensive regulations imposed by the FDA or other federal agencies could adversely impact cannabis sales and demand for products, potentially affecting financial results [204]. - The company is subject to ongoing tax audits, which could materially affect its tax provision, net income, and cash flows in future periods [164]. Debt and Financing - The company elected to defer an interest payment of approximately $2.8 million on the Term Loan on February 4, 2026, resulting in an event of default [175]. - The company has granted a continuing security interest in substantially all of its assets to JPMorgan, which may exercise remedies due to the default notice received [176]. - The company’s ability to service its debt is dependent on future performance, which is subject to various economic and competitive factors [177]. - The company’s Term Loan incurs interest at a floating rate, which may impact cash flows and financial condition as interest rates fluctuate [178]. - The existing Term Loan includes numerous financial and operating covenants that restrict the company's ability to incur additional indebtedness, pay dividends, and engage in certain transactions [179]. - The company is subject to risks related to compliance with the Term Loan, which could result in an event of default if covenants are breached, potentially leading to acceleration of debt obligations [180]. Cybersecurity and Technology Risks - The company may incur significant costs related to investigating and mitigating cyber threats, which could adversely affect its financial condition [160]. - The company’s cyber risk insurance may not cover all losses from breaches, and obtaining such insurance has become more difficult and expensive [160]. Environmental, Social, and Governance (ESG) Concerns - Increased scrutiny regarding environmental, social, and governance (ESG) practices may lead to higher operational costs and impact reputation [148]. - Approximately 19% of the company's peat bog sites are currently deemed non-compliant by environmental and legal authorities, affecting operational capabilities [144]. - The company may face significant costs related to compliance with environmental, health, and safety laws, which could impact its reputation and financial position [227]. Intellectual Property and Legal Risks - The company’s ability to protect its intellectual property rights is crucial for competitive advantage, and failure to do so could materially affect its business and financial results [230]. - Legal proceedings to enforce intellectual property rights may incur substantial costs and divert resources, potentially impacting the company's operations [232]. - The company may face litigation regarding intellectual property claims, which could result in significant expenses and distract personnel from their normal responsibilities [237]. Market and Stockholder Considerations - The company does not expect to pay any dividends to holders of common stock in the foreseeable future, as it intends to retain future earnings for business operations and expansion [245]. - The company is currently not in compliance with Nasdaq's continued listing standards, which could lead to delisting if compliance is not regained [246]. - The company may face significant challenges in raising additional financing if its common stock is delisted, negatively affecting the value and liquidity of its shares [248]. - The company has provisions in its corporate charter that could discourage or delay a change in control, potentially affecting stockholder voting power [241]. - The company has the authority to issue up to 50 million shares of preferred stock, which could dilute common stockholders' ownership and affect market prices [240].

Financial Transactions - The company sold purchased assets for a total consideration of $37.8 million in cash, with $18.9 million paid at closing and the remaining $18.9 million waived in connection with a private placement investment[94]. - GeneFab was provided an option to purchase up to 1,963,344 shares of common stock, valued at up to $20.0 million, at an exercise price of $10.18670, exercisable by August 7, 2026[95]. - The company will receive ten percent of the realized gains from GeneFab's parent company as part of the seller economic share agreement[96]. - An amendment to the GeneFab Framework Agreement was made, waiving the GeneFab Note Receivable and entering into an amended development and manufacturing services agreement[97]. Clinical Trials and Regulatory Approvals - The Celest Agreement includes collaboration for an investigator-initiated trial of the SENTI-301A gene circuit, with a Phase 1 clinical trial initiated in 2024[99]. - Celest Therapeutics has an exclusive option to obtain a license for SN301A, with potential aggregate payments of $156.0 million and tiered royalty payments if the option is exercised[100]. - The regulatory approval process for biologics requires substantial time and financial resources, including preclinical testing and submission of an IND to the FDA[110]. - The FDA's goal is to review standard BLA applications within ten months and priority review applications within six months after filing[124]. - Two adequate and well-controlled Phase 3 clinical trials are generally required by the FDA for BLA approval[122]. - The FDA may issue a Complete Response Letter (CRL) if the BLA is not approved in its current form, detailing deficiencies identified[126]. - Fast track designation allows for more frequent interactions with the FDA during product development and may qualify for priority review[129]. - Breakthrough therapy designation provides intensive FDA interaction and guidance beginning as early as Phase 1[130]. - Accelerated approval may be granted if the product shows an effect on a surrogate endpoint likely to predict clinical benefit[132]. - RMAT designation facilitates efficient development and expedited review for biologics intended to treat serious conditions[134]. - The FDA may require post-marketing studies to verify clinical benefits for products granted accelerated approval[132]. - The BLA submission requires a substantial application user fee unless a waiver applies[121]. - The FDA may withdraw product approval if compliance with pre- and post-marketing requirements is not maintained[128]. - On June 18, 2025, the FDA granted Orphan Drug Designation to SENTI-202 for treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia[136]. - Orphan drug designation provides financial incentives such as grant funding opportunities, tax advantages, and user-fee waivers[137]. - Orphan product exclusivity prevents the FDA from approving other applications for the same indication for seven years, with exceptions for clinical superiority or supply assurance[137]. - SENTI-202 received Regenerative Medicine Advanced Therapy (RMAT) designation in December 2025, facilitating expedited review and development[140]. - The FDA has 60 calendar days to determine if a drug meets RMAT criteria after a request is made[140]. - Biologics are subject to ongoing FDA regulation, including record-keeping, adverse experience reporting, and compliance with cGMP requirements[141]. - The FDA may withdraw approval if regulatory compliance is not maintained or if new problems are discovered post-market[142]. Market and Pricing Regulations - The Affordable Care Act established an abbreviated approval pathway for biosimilars, which must demonstrate no clinically meaningful differences from reference products[147]. - A biosimilar application cannot be submitted until four years after the reference product's first FDA license, with a 12-year exclusivity period for approval[149]. - Coverage and reimbursement for new products depend on decisions made by government health authorities and private insurers, impacting pricing and profitability[151]. - The Inflation Reduction Act of 2022 reduces out-of-pocket spending cap for Medicare Part D beneficiaries from $7,050 to $2,000 starting in 2025, effectively eliminating the coverage gap[161]. - The statutory minimum rebates under the Medicaid Drug Rebate Program have increased to 23.1% for most branded drugs and 13% for generic drugs[160]. - The American Rescue Plan Act of 2021 eliminated the statutory Medicaid drug rebate cap, previously set at 100% of a drug's average manufacturer price, for certain drugs starting January 1, 2024[160]. - The Budget Control Act of 2011 mandates a 2% reduction in Medicare payments to providers per fiscal year, effective through 2031[160]. - The Right to Try Act allows certain patients to access investigational drugs without enrolling in clinical trials, but manufacturers are not obligated to provide these drugs[160]. - Increased scrutiny over drug pricing practices has led to Congressional inquiries and proposed legislation aimed at enhancing transparency and reducing prescription drug costs[159]. - States are implementing aggressive regulations to control pharmaceutical pricing, which may include price constraints and marketing cost disclosures[164]. - Future healthcare reform measures may limit federal and state government payments for healthcare products, potentially reducing demand for current and future product candidates[165]. - Any denial of coverage or reimbursement from Medicare may lead to similar outcomes from private payors, impacting revenue generation and profitability[166]. - The implementation of the IRA's Medicare drug price negotiation program is currently subject to ongoing litigation, with uncertain effects on the business[161]. International Regulations and Exclusivity - The European Union grants eight years of data exclusivity and an additional two years of market exclusivity for new chemical entities or innovative medicinal products upon receiving marketing authorization[176]. - The overall exclusivity period can extend to a maximum of 11 years if the marketing authorization holder obtains new therapeutic indications that provide significant clinical benefits within the first eight years[176]. - Orphan medicinal products receive ten years of market exclusivity, which may be reduced to six years if the product no longer meets orphan designation criteria after five years[179]. - The European Commission introduced legislative proposals in April 2023 to replace the current regulatory framework for all medicines, with amendments proposed by the European Parliament in October 2023[180]. Company Operations and Workforce - As of March 19, 2026, the company had 39 full-time employees, with 7 holding Ph.D. or M.D. degrees[188]. - The company occupies approximately 40,000 square feet of office and R&D space in South San Francisco, with a lease expiring in April 2027[190]. - A cell therapy manufacturing facility was completed in June 2023, with a sublease agreement for 92,000 square feet of manufacturing space executed in August 2023, expiring in September 2032[191]. - The company qualifies as a smaller reporting company, allowing it to provide only two years of audited financial statements[192]. - The company’s common stock began trading on the Nasdaq Global Market under the symbol "SNTI" following a merger on June 8, 2022[194]. - Failure to comply with GDPR may result in fines up to €20 million or 4% of global annual revenues, whichever is higher[187].

Financial Performance - Net sales decreased by 32.7% to $25.1 million compared to $37.3 million in the prior year period, primarily due to a 27.3% decline in volume/mix of products sold and a 5.6% decrease in price [5]. - Gross Profit increased to $2.1 million, or 8.5% of net sales, compared to $1.8 million, or 4.9% of net sales, in the prior year period [6]. - Adjusted Gross Profit increased to $3.9 million, or 15.4% of net sales, compared to $3.6 million, or 9.6% of net sales, in the prior year period [6]. - Net loss increased to $242.2 million, or $(51.89) per diluted share, compared to a net loss of $17.5 million, or $(3.80) per diluted share, in the prior year period [8]. - Adjusted EBITDA improved to $(4.9) million compared to $(7.3) million in the prior year period, driven by higher Adjusted Gross Profit and lower Adjusted SG&A expenses [9]. - Net loss for the twelve months ended December 31, 2025, was $289.79 million, compared to a loss of $66.72 million in 2024, indicating a significant increase in losses [22]. Cost Management - SG&A expense decreased by 43.5% to $9.6 million compared to $17.0 million in the prior year period, while Adjusted SG&A expense decreased by 18.9% to $8.8 million [7]. - Selling, general and administrative expenses (SG&A) decreased from $72.79 million in 2024 to $59.95 million in 2025, a reduction of approximately 17.6% [21]. - Adjusted SG&A as a percentage of net sales improved to 29.4% in 2025 from 23.9% in 2024 [21]. - The Company is focused on reducing costs and improving productivity through operational changes, facility consolidation, and prioritizing proprietary brand offerings [11]. Cash Flow and Liquidity - Cash used in operating activities was $(4.0) million, with Free Cash Flow of $(4.3) million during the fourth quarter [10]. - The Company is exploring strategic alternatives to strengthen its liquidity and capital structure following an event of default on its Term Loan [10]. - Free Cash Flow for Q4 2025 was $(4.30) million, compared to $2.39 million in Q4 2024, showing a decline in cash generation [22]. - As of December 31, 2025, the Company had $6.3 million in cash and a principal balance of $114.4 million on its Term Loan outstanding [9]. Asset and Liability Changes - Total assets decreased from $426.1 million in 2024 to $123.8 million in 2025, a decline of approximately 71% [19]. - Current liabilities increased significantly from $34.99 million in 2024 to $140.03 million in 2025, representing a rise of over 300% [19]. - Total liabilities decreased slightly from $202.38 million in 2024 to $187.10 million in 2025, a reduction of about 7.5% [19]. Quarterly Performance - Adjusted Gross Profit for Q4 2025 was $3.86 million, up from $3.59 million in Q4 2024, reflecting an increase of 7.5% [21]. - Adjusted Gross Profit Margin improved to 15.4% in Q4 2025 from 9.6% in Q4 2024 [21]. - The company reported a gross profit of $2.13 million for Q4 2025, compared to $1.84 million in Q4 2024, marking an increase of 15.8% [21].

Corporate Governance and Legal Matters - Luckin Coffee Inc. terminated contractual arrangements with the Former VIE in March 2024, optimizing its corporate governance structure and eliminating the need for foreign restricted licenses[33]. - Legal proceedings and investigations related to the fabricated transactions have resulted in significant costs and could adversely affect the company's financial condition and operations[48]. - The company has faced challenges in obtaining insurance coverage for legal proceedings following the disclosure of fabricated transactions[48]. - The company has been subject to multiple legal proceedings and investigations related to the Fabricated Transactions, which could adversely affect its reputation, business, and financial condition[51]. - A penalty of RMB500,000 was imposed by the PRC tax authorities in 2022 due to corrections in VAT filings related to the Fabricated Transactions[51]. - As of April 2023, the company is facing legal proceedings in Singapore, with claims amounting to US$145.8 million from investors alleging losses due to the Fabricated Transactions[59]. - The company underwent an offshore restructuring, including the redemption of US$109.9 million of senior secured notes due 2027 as part of its debt management strategy[66]. - The company was delisted from Nasdaq on July 1, 2020, which has had a material adverse effect on the trading and price of its ADS[64]. - The ongoing legal issues and investigations may result in significant costs and management diversion, impacting the company's operational focus[52]. - Negative publicity surrounding the Fabricated Transactions could continue to adversely affect the company's business relationships and financial condition[62]. Financial Performance and Revenue - As of December 31, 2025, Luckin Coffee Inc. made cumulative capital contributions of $1,573.8 million to its PRC subsidiaries, which were accounted as loans[42]. - The company reported that its net revenue in 2019 was inflated by approximately RMB2.12 billion ($0.31 billion) due to fabricated transactions[46]. - Revenue from partnership stores was RMB11,593.7 million (US$1,654.8 million) in 2025, representing 23.5% of total revenues[83]. - The company reported operating income of RMB5,072.9 million (US$724.1 million) for the year ended December 31, 2025[85]. - The company has incurred significant operating losses since inception and may continue to do so in the future[85]. - The company has made RMB1,123.0 million in transfers from PRC subsidiaries to offshore entities for operational support[42]. - The company has experienced significant cash outflows from operating activities historically, raising concerns about future liquidity[119]. Market and Competition - The company faces intense competition in China's coffee industry, which may adversely affect its market share and profitability[84]. - The company may not be able to maintain its historical growth rates due to various external factors, including economic conditions and competition[73]. - The growth and profitability of the company depend significantly on customer demand and discretionary spending in China, with a downturn in the economy potentially leading to reduced customer spending[192]. Operational Challenges - The company relies on a limited number of suppliers for raw materials and delivery services, which poses risks to its operations[93][95]. - The company may face challenges in managing its store network, including identifying suitable locations and securing leases[109]. - Inventory management is critical, as the company deals with perishable goods, and mismanagement could lead to significant write-downs[186]. - The effectiveness of the company's quality control system is critical, as any failure could adversely impact its reputation and financial condition[97]. - Significant interruptions in operations of third-party suppliers could disrupt the company's operations, potentially leading to inventory shortages and affecting financial results[122]. Regulatory and Compliance Issues - The company faces risks associated with the Holding Foreign Companies Accountable Act, which could prohibit its securities from being traded if certain audit conditions are not met[39]. - The PRC government has significant authority over the company's operations, which could impact its ability to conduct business and accept foreign investments[37]. - Recent regulatory changes in China, including the Cybersecurity Law and Data Security Law, impose strict obligations on data handling and could lead to significant penalties for non-compliance[142]. - The company is required to comply with the PRC Cybersecurity Law and other related regulations, which may lead to increased scrutiny and operational challenges[154]. - The company must conduct personal information protection compliance audits at least once every two years if processing personal information of over 10 million individuals[149]. - The company has not faced monetary penalties related to payment processing compliance as of the report date, but future noncompliance could lead to fines and operational disruptions[159]. Strategic Initiatives and Future Plans - The company intends to invest significantly in branding, sales, marketing, and technology systems to improve brand awareness and customer retention[87]. - The company plans to explore expansion into overseas markets and continuously launch new product offerings[87]. - The company has entered into strategic partnerships, including with Weixin, which have historically benefited its business in mobile ordering, payment, and joint marketing[121]. - The company is exploring international market expansion, which exposes it to various risks including compliance, policy, and market challenges[131]. Risks and Liabilities - The company faces significant liability claims related to customer complaints about product quality, service, and long waiting times[169]. - Legal proceedings and claims may adversely affect the company's financial condition and results of operations, with potential substantial monetary damages[176]. - The company may face intellectual property infringement claims, which could disrupt operations and incur significant expenses[178]. - Limited insurance coverage may expose the company to significant costs and business disruptions, particularly regarding legal proceedings and investigations[195]. - The company is vulnerable to natural disasters and health epidemics, which could disrupt operations and adversely affect financial results[101]. Shareholder and Governance Issues - The controlling shareholder, Centurium Capital, holds 47.8% of the voting power, which may lead to decisions that are not aligned with the interests of other shareholders[206]. - The company’s operations are heavily influenced by the political, economic, and social conditions in China, which could materially affect financial performance and future prospects[209]. - Adverse changes in China's economic conditions or government policies could negatively impact the company's operations and competitive position[211]. - Legislative and regulatory developments related to overseas-listed China-based companies may have a material adverse impact on the company's listing and trading in the U.S.[226].

Financial Results - Autolus Therapeutics plc announced its financial results for the year ended December 31, 2025, during a conference call on March 27, 2026[5]. - The press release detailing the financial results is included as Exhibit 99.1[9]. Corporate Presentation - The company provided an updated corporate presentation as part of its disclosure, which is available as Exhibit 99.2[7].

Financial Performance - Senti Bio reported a net loss of $14.5 million, or $0.53 per share, for Q4 2025, and a full-year net loss of $61.4 million, or $2.73 per share[6]. - Total operating expenses for the full year 2025 were $68.8 million, compared to $61.0 million in 2024[15]. - The accumulated deficit increased to $358.6 million as of December 31, 2025, from $297.1 million in 2024[13]. - Senti Bio's total assets were reported at $51.2 million as of December 31, 2025, down from $97.8 million in 2024[13]. Research and Development - Research and development expenses for Q4 2025 were $7.8 million, consistent with Q4 2024, while total R&D expenses for the full year 2025 were $37.6 million, up from $34.4 million in 2024[5][15]. - The company received Regenerative Medicine Advanced Therapy (RMAT) designation for SENTI-202 for treating adults with relapsed or refractory acute myeloid leukemia (AML)[5]. - Positive preliminary clinical data from the ongoing Phase 1 trial of SENTI-202 showed encouraging response rates and a favorable safety profile[5]. General and Administrative Expenses - General and administrative expenses decreased to $5.8 million in Q4 2025 from $8.4 million in Q4 2024, with full-year G&A expenses totaling $26.2 million[5][15]. Cash Position - As of December 31, 2025, Senti Bio had cash and cash equivalents of approximately $16.4 million, down from $48.3 million in 2024[5][13]. Strategic Focus - The company is focused on advancing its Gene Circuit platform and key development milestones to deliver innovative therapies for serious diseases[2].

Financial Performance - Cost of revenue for Q4 2025 was $58 thousand, a significant decrease from $1.5 million in Q4 2024, and for the full year 2025, it was $0.7 million compared to $3.3 million in 2024[4] - Research and development expenses for Q4 2025 were $2.2 million, down from $3.4 million in Q4 2024, and for the full year 2025, they totaled $10.6 million compared to $12.2 million in 2024[5] - Selling, general and administrative expenses for Q4 2025 were $1.7 million, a decrease from $4.1 million in Q4 2024, and for the full year 2025, they were $10.6 million compared to $20.0 million in 2024[6] - Net loss for Q4 2025 was $3.3 million, a substantial reduction from a net loss of $57.4 million in Q4 2024, and for the full year 2025, the net loss was $25.1 million compared to $75.0 million in 2024[7] - Cash and cash equivalents as of December 31, 2025, were $17.1 million, down from $20.6 million as of December 31, 2024[8] Clinical Trials and Product Development - The company completed enrollment of the 209-patient FULCRUM-VT pivotal FDA Investigational Device Exemption trial, which is intended to support the premarket approval application for the vCLAS™ System[2] - Preliminary results from the FULCRUM-VT trial demonstrated 97% acute effectiveness with a favorable safety profile using the proprietary ultralow temperature technology[2] Strategic Initiatives - The company closed a private placement with gross proceeds of up to $50 million, with approximately $19 million expected to fund FDA submission activities and ongoing next-generation catheter development[2] - The company appointed Sean Salmon to the Board of Directors, enhancing strategic and governance expertise, and strengthened the executive leadership team with new senior vice presidents[2] - The company is focused on preparing for commercialization of the vCLAS™ technology while continuing to develop next-generation solutions for patients with ventricular tachycardia[3]

Competition and Market Challenges - The company faces intense competition in the browser market from major players like Google, Apple, and Microsoft, which may limit its ability to expand distribution and monetize its user base [32]. - The company is experiencing challenges in user growth and engagement, particularly in markets where monetization potential is lower, which could adversely affect its financial performance [31]. - The company is focusing on attracting higher-value users in Western markets, which may lead to slower growth in other regions [29]. - The company's advertising revenues may decline if AI systems shift user engagement away from traditional browsing and toward AI-generated content [53]. - The company relies on third-party distribution channels, which may change or restrict access to its products, adversely affecting user acquisition and engagement [159]. Revenue and Financial Risks - A significant portion of the company's revenue is derived from user query activities within its browsers, with a substantial reliance on Google for query monetization [44]. - The company is exposed to risks related to revenue concentration, with a limited number of partners accounting for a significant share of its total revenues, particularly from Google [41]. - Geographic concentration of revenue sources exposes the company to risks related to economic conditions and regulatory developments in specific jurisdictions [42]. - Global economic conditions, including inflation and geopolitical conflicts, could adversely affect advertising spending and overall revenue [73]. - The company may require additional capital for future growth, product development, or potential investments or acquisitions [89]. Technology and Innovation - The integration of AI technologies into the company's products presents both opportunities and risks, as it may change user behavior and reduce traditional browsing activity [51]. - The company is investing in new technologies and features, including AI-enabled functionality, to remain competitive, but these initiatives carry execution and commercial risks [40]. - The company continuously invests in upgrading its technology infrastructure, which requires significant ongoing investment of time and resources [110]. - The company relies on a combination of internally developed systems and third-party AI models, which could impair operations if disrupted [116]. Legal and Regulatory Environment - Legal and regulatory developments affecting Google and other search providers could impact the company's query revenue and distribution arrangements [49]. - The company is subject to evolving privacy and consumer protection laws, which may impose additional obligations and increase compliance costs [135]. - The company is subject to a complex set of legal and regulatory requirements across multiple jurisdictions, which may increase compliance costs and limit operational flexibility [189]. - Compliance with multiple regulatory regimes may increase costs and limit operational flexibility, potentially affecting the company's financial condition and market price of its ADSs [190]. Operational and Security Risks - The company faces significant costs associated with modifying or redeveloping products and services to keep pace with technological developments [56]. - Cybersecurity threats are increasingly sophisticated, and the company has experienced attempts to gain unauthorized access to its systems [137]. - The company must maintain reliable access to internet infrastructure, and disruptions could materially affect its business and financial condition [163]. - The company is exposed to operational risks from third-party service providers, which may experience outages or disruptions [152]. Investment and Asset Management - The company has invested in new businesses and technologies, including gaming and artificial intelligence, but these may not achieve expected growth or profitability [66]. - The carrying amount of the investment in OPay was $294.6 million as of December 31, 2025, and its valuation is highly uncertain, classified as Level 3 within the fair value hierarchy [170]. - Changes in the fair value of the OPay investment are recognized directly in profit or loss, which may result in substantial gains or losses, causing significant volatility in reported results and equity [173]. Corporate Governance and Shareholder Rights - Kunlun indirectly owns approximately 68.0% of the outstanding ordinary shares, allowing it to control significant corporate decisions, which may not align with the interests of other shareholders [183]. - The Board of Directors has the authority to issue preferred shares without shareholder approval, which could complicate any change of control or management removal [199]. - Shareholder rights under Cayman Islands law may be more limited compared to U.S. law, affecting the ability to pursue actions against directors or the company [202]. - Holders of ADSs may have limited ability to exercise voting rights directly, requiring adherence to the deposit agreement for voting instructions [213].